20958-18-3
基本信息
二氫異丹參酮I
8-二甲基-8
9-二氫菲并[3
2-B]呋喃-7
去氫異丹參酮 I
二氫丹參酮(標準品)
4,8-二甲基-8,9-二氫菲并[3,2-b]呋喃-7,11-二酮
Dihydrotanshinone
Dihydroisotanshinone I
8,9-Dihydro-4,8-dimethylphenanthro[3,2-b]furan-7,11-dione
4,8-Dimethyl-8,9-dihydrophenanthro[3,2-b]furan-7,11-dione
Phenanthro(3,2-B)furan-7,11-dione, 8,9-dihydro-4,8-dimethyl-
4,8-Dimethyl-8,9-Dihydronaphtho[2,1-F][1]BenzofuraN-7,11-Dione
Dihydrotanshinone 4,8-Dimethyl-8,9-dihydrophenanthro[3,2-b]furan-7,11-dione
物理化學性質
報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
2022/07/01 | HY-B1919 | 二氫丹參酮 Dihydroisotanshinone I | 20958-18-3 | 5mg | 1800元 |
2022/07/01 | HY-B1919 | 二氫丹參酮 Dihydroisotanshinone I | 20958-18-3 | 10mM * 1mLin DMSO | 2380元 |
2022/07/01 | HY-B1919 | 二氫丹參酮 Dihydroisotanshinone I | 20958-18-3 | 10mg | 2800元 |
常見問題列表
STAT3
|
Dihydroisotanshinone I can inhibit the migration of both androgen-dependent and androgen-independent prostate cancer cells. Dihydroisotanshinone diminishes the ability of prostate cancer cells to recruit macrophages and reduces the secretion of chemokine (C-C motif) ligand 2 (CCL2) from both macrophages and prostate cancer cells in a dose-dependent manner. It inhibits the protein expression of p-STAT3 and decreases the translocation of STAT3 into nuclear chromatin. It also suppresses the expression of tumor epithelial-mesenchymal transition genes, including RhoA and SNAI1. Pretreating the cells with dihydroisotanshinone I at concentrations ranging from 2.5 μM to 20 μM for 24 hours cause dose-dependent protection against hepatotoxicity induced by menadione. Adding dihydroisotanshinone I to freshly isolated hepatocytes at concentrations between 50 nM to 200 nM inhibit NADH-induced superoxide production dose-dependently.